Monday, October 17, 2022 Daily Archives

Purolite tripling resin capacity with manufacturing expansion

by

Purolite has cut the ribbon on the latest expansion at its chromatography resin production site in Wales, UK. Purolite manufactures resins out of agarose, a material originating from red seaweed. The firm turns the agarose into tiny beads, typically between 35 and 200 microns in size, which are then used as a raw material by biomanufacturers to purify monoclonal antibody therapies. The expansion at the Llantrisant site – located about 20km northwest of Cardiff – will treble Purolite’s capacity and…

October 17, 2022

BioPlan report: Buoyant bioprocess space will continue to shine post-COVID

by

Automation, innovation, and process optimization are driving higher yields, lower costs, and multiple capacity options for biomanufacturers, says BioPlan Associate’s Eric Langer. Ahead of the trade show on November 1-3, BioPlan Associates produced an article for the CPHI Frankfurt Annual Report, presenting a detailed analysis of the findings from its Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production and predicting key trends for the future of biomanufacturing. The key takeaways are: Industry growth: Over the past 10 years…

October 17, 2022

AAVs: The future of gene therapies, but what will it take to make them stable?

by

Characterize adeno-associated viruses (AAVs) for aggregation, stability, and particles at low volume for accelerated development of life-saving gene therapies. Development can further be accelerated by monitoring critical quality attribute parameters like subvisible particles (SVP) concentration early in the development process. Capsid degradation and nucleic acid leakage can both occur under different formulation and storage conditions and contribute to the accumulation of aggregates. Characterizing candidates earlier in the development process is best as it identifies and eliminates inherently unstable candidates before…

October 17, 2022

AAV platform speeds gene therapy programs, says Charles River

by

Charles River Laboratories has launched its nAAVigation vector platform, which it says has the ability to reduce a gene therapy developers program timeline by 55%. According to Charles River Laboratories (CRL), its nAAVigation platform has been designed using its adeno-associated virus (AAV) vector contract development and manufacturing organization (CDMO) experience. The company claims that its nAAVigation technology removes the need for significant process development by streamlining the pathway to AAV vector production. Additionally, CRL says that the 55% reduction to…

October 17, 2022